New Zealand Faces Potential Medicine Shortages Amid Global Risks

New Zealand could experience critical shortages of essential medicines if global trade faces significant disruptions, researchers have warned. A recent study published in The New Zealand Medical Journal highlights that none of the country’s ten most commonly prescribed medications, which include paracetamol, amoxicillin, metoprolol, and salbutamol, can be produced locally.

The study’s co-author, Professor Nick Wilson from Otago University, stated that in the event of a catastrophe, such as a nuclear conflict or widespread pandemic, New Zealand’s medicine supplies could deplete rapidly. He emphasized the nation’s vulnerability, saying, “This is a high level of vulnerability in a post-catastrophe situation.”

Reliance on Imports and Risks of Shortages

The primary concern stems from New Zealand’s dependence on imported petrochemical ingredients, as the country lacks local refining facilities to produce them. Without these critical components, stocks of essential medicines could run out, potentially resulting in preventable deaths associated with infections, heart disease, and asthma.

The study evaluated various medications, including:

– Paracetamol
– Omeprazole (used for acute gastritis and gastric ulcers)
– Amoxicillin (for severe bacterial pneumonia)
– Ibuprofen (for pain relief)
– Aspirin (for managing strokes and heart attacks)
– Metoprolol (for blood pressure regulation)
– Salbutamol (for asthma)
– Prednisone (a steroid for severe allergic reactions)
– Cetirizine (an antihistamine)
– Amlodipine (for angina)

Globally, the production of pharmaceuticals is heavily centralized, with up to 80% of active pharmaceutical ingredients sourced from China and India. This concentration heightens the risk for countries like New Zealand, which rely heavily on these imports.

Proposed Solutions for Resilience

To mitigate these risks, researchers suggest establishing partnerships with Australia, which maintains petrochemical production capabilities and has the capacity to produce morphine from opium poppies. They also recommend exploring small-scale local manufacturing options and investigating natural substitutes, such as willow bark for aspirin.

Dr. Matt Boyd, another co-author of the study, indicated that a collaborative plan between New Zealand and Australia could enhance the manufacturing and trading of essential medicines. “New Zealand plans well for earthquakes,” Wilson noted, “but our biggest threats to medicine supply could come from beyond our shores.”

The findings serve as a wake-up call for New Zealand, prompting discussions on how to bolster its medicine supply chain and ensure that essential treatments remain accessible to its population, especially in the face of unpredictable global events.